Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.46 |
| ▸ | ERN1 | O75460 | 1/20 | 0.46 |
| ▸ | TLR2 | O60603 | 5/20 | 0.40 |
| ▸ | TLR1 | Q15399 | 5/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | AMY1A | P0DUB6 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7886140 | 0.84 | TLR2 (0.45) | ALDH1A1TLR2TLR1MAPTPOLB | |
| SCHEMBL3745954 | 0.82 | ALDH1A1 (0.44) | ALDH1A1TLR2TLR1MAPTPOLB | |
| SCHEMBL10153120 | 0.81 | ALDH1A1 (0.49) | ALDH1A1ERN1TLR2TLR1MAPT | |
| SCHEMBL10153280 | 0.80 | PDE3B (0.34) | — | |
| SCHEMBL8152746 | 0.80 | ALDH1A1 (0.41) | ALDH1A1TLR2TLR1MAPTPOLB | |
| SCHEMBL1041160 | 0.80 | KMT2A (0.45) | ALDH1A1TLR2TLR1MAPTPOLB | |
| SCHEMBL1698972 | 0.76 | MAPT (0.52) | ALDH1A1TLR2TLR1MAPTPOLB | |
| SCHEMBL11025617 | 0.74 | HTT (0.45) | ALDH1A1TLR2TLR1HTTKMT2A | |
| SCHEMBL8135570 | 0.71 | TLR2 (0.39) | ALDH1A1TLR2TLR1MAPTPOLB | |
| SCHEMBL9591597 | 0.71 | ALDH1A1 (0.47) | ALDH1A1TLR2TLR1MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772504-B2 | Substituted benzoxazole, benzimidazole, oxazolopyridine and imidazopyridine derivatives as gamma secretase modulators | Janssen Pharmaceuticals, Inc. (US) | 2014-07-08 | — | — | US | disclosed |
| US-20120022090-A1 | NOVEL SUBSTITUTED BENZOXAZOLE, BENZIMIDAZOLE, OXAZOLOPYRIDINE AND IMIDAZOPYRIDINE DERIVATIVES AS GAMMA SECRETASE MODULATORS | CELLZOME LIMITED (GB) | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022090-A1 | NOVEL SUBSTITUTED BENZOXAZOLE, BENZIMIDAZOLE, OXAZOLOPYRIDINE AND IMIDAZOPYRIDINE DERIVATIVES AS GAMMA SECRETASE MODULATORS | BACE1, BACE2, GSAP | ALDH1A1 1693/4885ERN1 2394/4885TLR2 4138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.